Insight Molecular Diagnostics Inc. Common Stock (IMDX)

• Market cap: $81.5M
• 1 day: -2.69%
• 5 days: -5.25%
• 1 month: 4.71%
• 3 months: -0.34%
• 6 months: 30.77%
• Year to date: 24.03%
• 1 year: -4.30%
• 5 years: -88.80%
• 10 years: -98.39%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.

Employees: 49

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

146% more capital invested

Capital invested by funds: $20M [Q4 2024] → $49.2M (+$29.2M) [Q1 2025]

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

15% more funds holding

Funds holding: 26 [Q4 2024] → 30 (+4) [Q1 2025]

6.29% more ownership

Funds ownership: 49.97% [Q4 2024] → 56.27% (+6.29%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]